AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations
Amarin’s AMRN shares surged nearly 17% following the release of preliminary sales numbers for fourth-quarter and full-year 2025, which exceeded expectations.Amarin’s top line currently comprises product revenues from Vascepa/Vazkepa (Vascepa’s brand name in Europe), complemented by licensing and royalty revenues.Vascepa (icosapent ethyl) is approved as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride (TG) levels (≥500 mg/dL). It is also approved to reduce cardiovascular risk (CV) in patients with persistently elevated triglycerides on statin therapy for LDL-C.Q4 & FY2025 Preliminary ResultsAmarin expects preliminary total revenues for the fourth quarter to be in the range of $48 million to $53 million. The preliminary sales came in higher than the Zacks Consensus Estimate of $43 million.For full-year 2025, preliminary total revenues are expected to be between $212 million and $217 million, above the Zacks Consensus Estimate of $207 million.Restructuring costs are expected to range from $37-$40 million for full-year 2025, up from the prior estimate of $30-$37 million.Amarin has already achieved approximately 50% of its planned $70 million operating expense reductions, with a plan to realize the full benefits by June 2026, supporting a lower operating cost structure and sustainable profitability.The company achieved positive cash flow in the fourth quarter of 2025, which was earlier than its prior expectation of 2026. This may have also contributed to the stock’s rise on Thursday.Amarin ended 2025 with approximately $303 million in cash and investments, up from $287 million in the third quarter of 2025 and remained debt-free, which further reduces the company’s financial risk.Over the past year, shares of Amarin have risen 48.6% compared with the industry’s 19.2% growth.Image Source: Zacks Investment Research2026 OutlookIn June, Amarin signed an exclusive long-term license and supply agreement with Italy-based pharma company, Recordati, to commercialize Vazkepa in 59 countries, mainly across the European Union. The company has signed partnership deals with seven experienced partners providing access to nearly 100 markets. Per management, the fully partnered ex-U.S. business model should help reduce costs and achieve positive annual cash flow in 2026.Vascepa/Vazkepa is approved in over 50 countries and protected by patents in Europe until 2039.Amarin’s Zacks Rank & Stocks to ConsiderAMRN currently carries a Zacks Rank #4 (Sell).Some better-ranked stocks in the biotech sector are Amicus Therapeutics FOLD, CorMedix CRMD and Indivior INDV, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. Shares of FOLD have increased 58.3% over the past year.Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters with the negative average surprise being 20.21%.Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have declined 32.9% over the past year.CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.Over the past 60 days, estimates for Indivior’s 2026 earnings per share have risen to $2.85 from $2.60. Indivior stock has rallied 199.6% over the past year.Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.Free Report: Profiting from the 2nd Wave of AI ExplosionThe next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.Investors who bought shares like Nvidia at the right time have had a shot at huge gains.But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.Access AI Boom 2.0 now, absolutely free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report Amarin Corporation PLC (AMRN): Free Stock Analysis Report CorMedix Inc (CRMD): Free Stock Analysis Report Indivior PLC (INDV): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Quelle: Zacks